BACKGROUND
• Family members of patients with established inherited cardiopathies may be carriers of the causative mutation and be at risk of sudden cardiac death (SCD) 1 • Genetic testing could prevent SCD in asymptomatic first-degree relatives of patients with established inherited cardiopathies 2 .
OBJECTIVES
• The objective is to estimate the cost-effectiveness of conducting genetic testing in first-degree relatives of patients with: 1. Hypertrophic Cardiomyopathy (HCM); 2. Arrhythmogenic Right Ventricular Cardiomyopathy (ARVC); 3. Long-QT Syndrome (LQTS); 4. Brugada Syndrome (BrS); 5. Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT) in Spain.
METHODS
• A Markov model was developed to determine the cost per life-year gained (LYG) and per symptomfree years (SFY) gained of conducting genetic testing in first-degree relatives at risk of SCD due to gene-related cardiopathies compared to real clinical practice (with no genetic testing).
• The target population was defined as hypothetical cohorts of 1,000 patients (a cohort per cardiopathy) followed over their lifetime.
• Four health states were defined as follows: 1. Asymptomatic; 2. Minor events (palpitations, dizziness, fatigue, chest pain, dyspnea) 3. Major events (syncope, aborted SCD); and 4. Death (figure 1) • The analysis was conducted from the Spanish National Health System (NHS) perspective. Only direct costs were taken into account. Future costs and effects were discounted at a 3% rate per year. All costs referred to €,2012. • It was assumed that patients would enter the model at age 18 years as asymptomatic individuals, and every year, they could either remain in their current health state or move to a different one.
• Probabilities of transitions among health states (base case scenario) are summarized in Table 1 . It was conceived that pharmacological treatment and Implantable Cardioverter Desfibrilator (ICD) would reduce the probabilities of minor and major events, respectively. Data were derived from relevant trials and registries, and complemented the experts' opinion in case of insufficient data. • It was also assumed that asymptomatic patients with negative mutations did not require follow-up while those with positive mutations would require it. Although those with LQTS or CPVT would receive prophylactic treatment. All patients with no genetic testing would require follow-up ( Figure 2 ). • Patients with minor events required follow-up and pharmacological treatment. In case of major events an ICD was also used.
• Table 2 describes the probabilities of identifying gene-related cardiopathies with clinical screening alone; of identifying a mutation within an index case; and the prevalence of mutations in first-degree family members. • The corresponding use of resources for diagnosis, follow-up and treatment were estimated. Costs were calculated by multiplying the number of resource items consumed (expert opinion) by the unit costs (local databases) of resources. The costs data inputted to the model is presented in Table 3 . Figure 3 illustrates the mean cost per patient for both comparators and the difference in costs for each gene-related cardiophaty.
Figure 3: Mean cost per patient (€)
• For LQTS and CPTV, genetic testing implied 0.96 and 0.04 SFY increase, and 0.01 and 0,04 LYG, respectively, per patient compared to clinical practice. These variables remained unchanged for HCM, ARVC and BrS.
• Genetic testing was more effective and less costly (superior) for LQTS and CPTV.
• For HCM, ARVC and BrS it was almost equally effective and less costly (dominant) than usual practice (Table 4) : 
